Sustained hematologic effects of hydroxyurea therapy at MTD for pediatric patients with SCD
Year . | No. patients . | Hb level, g/dL . | MCV, fL . | HbF level, % . | WBC count, × 109/L . | ANC, × 109/L . | Reticulocyte, × 109/L . | Platelet count, × 109/L . | Bilirubin level, mg/dL . | Hydroxyurea dose, mg/kg daily . |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 122 | 8.2 ± 1.2 | 84 ± 9 | 7.6 ± 5.5 | 12.4 ± 3.8 | 6.2 ± 2.9 | 347 ± 138 | 486 ± 192 | 3.3 ± 2.5 | NA |
| 1 | 122 | 9.5 ± 1.1 | 104 ± 13 | 20.6 ± 8.1 | 7.7 ± 2.7 | 3.6 ± 1.9 | 181 ± 115 | 370 ± 150 | 1.9 ± 1.4 | 24.9 ± 5.4 |
| 2 | 97 | 9.6 ± 1.3 | 105 ± 12 | 20.3 ± 7.5 | 7.2 ± 2.7 | 3.5 ± 1.9 | 181 ± 90 | 349 ± 132 | 2.0 ± 1.6 | 24.4 ± 5.3 |
| 3 | 70 | 9.8 ± 1.3 | 106 ± 12 | 19.8 ± 8.2 | 7.0 ± 2.9 | 3.4 ± 2.1 | 181 ± 84 | 406 ± 190 | 2.0 ± 1.4 | 25.0 ± 5.7 |
| 4 | 48 | 10.0 ± 1.3 | 106 ± 13 | 19.4 ± 8.5 | 7.1 ± 2.8 | 3.4 ± 2.1 | 189 ± 95 | 374 ± 199 | 1.9 ± 1.5 | 25.7 ± 4.8 |
| 5 | 36 | 9.9 ± 1.4 | 107 ± 18 | 20.3 ± 9.1 | 6.3 ± 2.2 | 3.0 ± 1.4 | 160 ± 87 | 395 ± 201 | 1.7 ± 1.3 | 25.8 ± 4.9 |
| 6 | 18 | 9.9 ± 1.4 | 106 ± 13 | 19.6 ± 8.1 | 6.7 ± 2.5 | 3.0 ± 1.3 | 212 ± 107 | 366 ± 175 | 1.7 ± 1.3 | 25.7 ± 4.7 |
| 7 | 9 | 10.0 ± 1.2 | 112 ± 13 | 21.9 ± 5.1 | 6.1 ± 2.4 | 2.7 ± 1.2 | 197 ± 71 | 390 ± 139 | 2.4 ± 1.3 | 24.7 ± 3.1 |
Year . | No. patients . | Hb level, g/dL . | MCV, fL . | HbF level, % . | WBC count, × 109/L . | ANC, × 109/L . | Reticulocyte, × 109/L . | Platelet count, × 109/L . | Bilirubin level, mg/dL . | Hydroxyurea dose, mg/kg daily . |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 122 | 8.2 ± 1.2 | 84 ± 9 | 7.6 ± 5.5 | 12.4 ± 3.8 | 6.2 ± 2.9 | 347 ± 138 | 486 ± 192 | 3.3 ± 2.5 | NA |
| 1 | 122 | 9.5 ± 1.1 | 104 ± 13 | 20.6 ± 8.1 | 7.7 ± 2.7 | 3.6 ± 1.9 | 181 ± 115 | 370 ± 150 | 1.9 ± 1.4 | 24.9 ± 5.4 |
| 2 | 97 | 9.6 ± 1.3 | 105 ± 12 | 20.3 ± 7.5 | 7.2 ± 2.7 | 3.5 ± 1.9 | 181 ± 90 | 349 ± 132 | 2.0 ± 1.6 | 24.4 ± 5.3 |
| 3 | 70 | 9.8 ± 1.3 | 106 ± 12 | 19.8 ± 8.2 | 7.0 ± 2.9 | 3.4 ± 2.1 | 181 ± 84 | 406 ± 190 | 2.0 ± 1.4 | 25.0 ± 5.7 |
| 4 | 48 | 10.0 ± 1.3 | 106 ± 13 | 19.4 ± 8.5 | 7.1 ± 2.8 | 3.4 ± 2.1 | 189 ± 95 | 374 ± 199 | 1.9 ± 1.5 | 25.7 ± 4.8 |
| 5 | 36 | 9.9 ± 1.4 | 107 ± 18 | 20.3 ± 9.1 | 6.3 ± 2.2 | 3.0 ± 1.4 | 160 ± 87 | 395 ± 201 | 1.7 ± 1.3 | 25.8 ± 4.9 |
| 6 | 18 | 9.9 ± 1.4 | 106 ± 13 | 19.6 ± 8.1 | 6.7 ± 2.5 | 3.0 ± 1.3 | 212 ± 107 | 366 ± 175 | 1.7 ± 1.3 | 25.7 ± 4.7 |
| 7 | 9 | 10.0 ± 1.2 | 112 ± 13 | 21.9 ± 5.1 | 6.1 ± 2.4 | 2.7 ± 1.2 | 197 ± 71 | 390 ± 139 | 2.4 ± 1.3 | 24.7 ± 3.1 |
Values are expressed as mean ± SD. For a few patients receiving chronic transfusions for stroke prophylaxis, baseline values were not available for all laboratory parameters. For all comparisons between baseline and year 1, P < .001. There were no statistically significant changes in hematologic parameters for subsequent year-to-year comparisons.
NA indicates not applicable.